跳至主要内容
临床试验/NCT06335290
NCT06335290招募中不适用

Radiotherapy Treatments for the Treatment of Thoracic District Tumors

European Institute of Oncology1 个研究点 分布在 1 个国家目标入组 13,200 人开始时间: 2018年2月22日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
13,200
试验地点
1
主要终点
Overall survival

研究概览

简要总结

Evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of thoracic radiotherapy treatments in patients undergoing radiotherapy for primary or secondary neoplasms localized in the thoracic anatomical region.

详细描述

Approximately 60% of patients with neoplasms receive radiotherapy as part of their oncological treatment.

Various primary tumors as well as metastases of various origins can be localized in the thoracic anatomical region.

Patients with such neoplastic localizations will therefore receive radiotherapy treatment possibly associated with other systemic or surgical treatments.

Treatment choice is usually established following multidisciplinary discussions, based on disease characteristics and stage, concurrent pathologies and pharmacological treatments, patient preferences, and functional aspects.

The collection of data related to radiotherapy plays a crucial role in understanding various clinical aspects of the treatment itself. The availability of data from an increasing number of patients will allow the identification of clinical situations or technical parameters of radiotherapy correlated with treatment tolerance and effectiveness, aiming to identify the best treatment for these oncological pathologies. This project aims to collect data related to radiotherapy treatments for primary or secondary neoplasms of the thoracic region for scientific dissemination with the goal of establishing the basis for evaluating achieved results over time, and deriving from these elements useful for guiding the most effective treatment strategies and appropriate operational protocols.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the thoracic region include those with:
  • Primary bone tumors,
  • Primary soft tissue tumors,
  • Primary tumors of the cardio-circulatory system,
  • Primary tumors of the lymphatic system,
  • Primary tumors of the nervous system and skin,
  • Secondary metastases from various origins localized in the thoracic region.
  • Signed informed consent

排除标准

  • Radiotherapy in districts other than the thoracic region.

结局指标

主要结局

Overall survival

时间窗: 5 years

Number of patients death

Disease free survival

时间窗: 5 years

Number of oncological event (local recurrence, distant metastasis, other primary tumor)

次要结局

未报告次要终点

研究者

发起方
European Institute of Oncology
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验